New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Evidence for link between 'leaky gut' and autoantibody production in HIV-positive patients

Evidence for link between 'leaky gut' and autoantibody production in HIV-positive patients

by Medical University of South CarolinaHIV-positive, ART-treated patients with high levels of autoantibodies also have increased levels of bacteria (Staphylococcus aureus) products in their blood
Immunology & Rheumatology April 16,2024
Evidence for link between 'leaky gut' and autoantibody production in HIV-positive patients

Evidence for link between 'leaky gut' and autoantibody production in HIV-positive patients

by Medical University of South CarolinaHIV-positive, ART-treated patients with high levels of autoantibodies also have increased levels of bacteria (Staphylococcus aureus) products in their blood
Immunology & Rheumatology April 16,2024
HIV: An antidiabetic drug to reduce chronic inflammation

HIV: An antidiabetic drug to reduce chronic inflammation

by University of Montreal Hospital Research CentreScanning electromicrograph of an HIV-infected T cell. Credit: NIAIDMetformin, a drug used to treat type-2 diabetes, could help reduce chronic inflamma
Public Health & Prevention April 16,2024
HIV: An antidiabetic drug to reduce chronic inflammation

HIV: An antidiabetic drug to reduce chronic inflammation

by University of Montreal Hospital Research CentreScanning electromicrograph of an HIV-infected T cell. Credit: NIAIDMetformin, a drug used to treat type-2 diabetes, could help reduce chronic inflamma
Public Health & Prevention April 16,2024
HIV infection leaves a 'memory' in cells

HIV infection leaves a 'memory' in cells

by George Washington UniversityImage of HIV. Credit: C. GoldsmithContent Providers: CDC/ C. Goldsmith, P. Feorino, E. L. Palmer, W. R. McManusThough antiretroviral therapy has made HIV a manageab
Public Health & Prevention April 16,2024
HIV infection leaves a 'memory' in cells

HIV infection leaves a 'memory' in cells

by George Washington UniversityImage of HIV. Credit: C. GoldsmithContent Providers: CDC/ C. Goldsmith, P. Feorino, E. L. Palmer, W. R. McManusThough antiretroviral therapy has made HIV a manageab
Public Health & Prevention April 16,2024
Remission from HIV-1 infection: Discovery of broadly neutralizing antibodies that contribute to virus control

Remission from HIV-1 infection: Discovery of broadly neutralizing antibodies that contribute to virus control

by Pasteur InstituteAntibody fragments of EPCT112 bNAb (blue) discovered at the Institut Pasteur by Hugo Mouquet's team, here forming a complex with the HIV-1 envelope protein (Env) (shown in
Public Health & Prevention April 16,2024
Remission from HIV-1 infection: Discovery of broadly neutralizing antibodies that contribute to virus control

Remission from HIV-1 infection: Discovery of broadly neutralizing antibodies that contribute to virus control

by Pasteur InstituteAntibody fragments of EPCT112 bNAb (blue) discovered at the Institut Pasteur by Hugo Mouquet's team, here forming a complex with the HIV-1 envelope protein (Env) (shown in
Public Health & Prevention April 16,2024
Identification of LZTR1 leads to novel insights into RAS-driven diseases

Identification of LZTR1 leads to novel insights into RAS-driven diseases

by VIB (the Flanders Institute for Biotechnology)Cancer cell during cell division. Credit: National Institutes of HealthMutations in RAS proteins initiate many of the most aggressive tumors, and
Immunology & Rheumatology April 16,2024
Identification of LZTR1 leads to novel insights into RAS-driven diseases

Identification of LZTR1 leads to novel insights into RAS-driven diseases

by VIB (the Flanders Institute for Biotechnology)Cancer cell during cell division. Credit: National Institutes of HealthMutations in RAS proteins initiate many of the most aggressive tumors, and
Immunology & Rheumatology April 16,2024
HDL composition may help predict health risks and design therapeutics

HDL composition may help predict health risks and design therapeutics

by Pat Bailey,UC DavisNutrition researcher Angela Zivkovic and colleagues have found that the amounts and specific structure of complex sugars called glycans can powerfully influence the body’s
Immunology & Rheumatology April 16,2024
HDL composition may help predict health risks and design therapeutics

HDL composition may help predict health risks and design therapeutics

by Pat Bailey,UC DavisNutrition researcher Angela Zivkovic and colleagues have found that the amounts and specific structure of complex sugars called glycans can powerfully influence the body’s
Immunology & Rheumatology April 16,2024
Another step toward the HIV-1 vaccine: Dynamics of neutralizing antibodies

Another step toward the HIV-1 vaccine: Dynamics of neutralizing antibodies

by University of CologneNeutralization screening of a large multinational cohort.a, Isolated IgGs of 2,354 HIV-1-infected individuals from a multinational study were tested against the glob
Public Health & Prevention April 16,2024
Another step toward the HIV-1 vaccine: Dynamics of neutralizing antibodies

Another step toward the HIV-1 vaccine: Dynamics of neutralizing antibodies

by University of CologneNeutralization screening of a large multinational cohort.a, Isolated IgGs of 2,354 HIV-1-infected individuals from a multinational study were tested against the glob
Public Health & Prevention April 16,2024
HIV antibody therapy is associated with enhanced immune responses in infected individuals

HIV antibody therapy is associated with enhanced immune responses in infected individuals

by University of Montreal Hospital Research CentreMicroscopic image of an HIV-infected T cell. Credit: NIAIDMost people living with HIV control the virus thanks to antiretroviral therapy (ART). Althou
Public Health & Prevention April 16,2024
HIV antibody therapy is associated with enhanced immune responses in infected individuals

HIV antibody therapy is associated with enhanced immune responses in infected individuals

by University of Montreal Hospital Research CentreMicroscopic image of an HIV-infected T cell. Credit: NIAIDMost people living with HIV control the virus thanks to antiretroviral therapy (ART). Althou
Public Health & Prevention April 16,2024
HIV: Reprogramming cells to control infection

HIV: Reprogramming cells to control infection

by Pasteur InstituteMicroscopic image of an HIV-infected T cell. Credit: NIAIDCells from the rare individuals who naturally control HIV infection have been the focus of investigation for nearly 1
Public Health & Prevention April 16,2024
HIV: Reprogramming cells to control infection

HIV: Reprogramming cells to control infection

by Pasteur InstituteMicroscopic image of an HIV-infected T cell. Credit: NIAIDCells from the rare individuals who naturally control HIV infection have been the focus of investigation for nearly 1
Public Health & Prevention April 16,2024
HIV-infected cells persist in CSF in individuals on long-term ART

HIV-infected cells persist in CSF in individuals on long-term ART

(HealthDay)—About half of HIV-positive individuals on long-term antiretroviral therapy (ART) have HIV-infected cells in their cerebrospinal fluid (CSF), according to a study published online July 15 i
Public Health & Prevention April 16,2024
HIV-infected cells persist in CSF in individuals on long-term ART

HIV-infected cells persist in CSF in individuals on long-term ART

(HealthDay)—About half of HIV-positive individuals on long-term antiretroviral therapy (ART) have HIV-infected cells in their cerebrospinal fluid (CSF), according to a study published online July 15 i
Public Health & Prevention April 16,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com